| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6879
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate |
2017-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-109311964-B |
| titleOfInvention |
Fusion proteins with increased eye retention for ophthalmology |
| abstract |
A combination of a first binding site that specifically binds to a target associated with eye disease and a second binding site that specifically binds a target that affects ocular retention, the multispecific binding agent provides improved intravitreal compared to monospecific binding agents reserve. The second binding site specifically binds compounds/molecules found in the extracellular matrix (ECM) in the vitreous humor/retina. The extracellular matrix compound must be present in an amount that allows a sufficient load/dose of the drug to be bound. Collagen, especially collagen II, has been found to be a suitable compound in the ECM in the vitreous humor for this purpose. Thus, reported herein are multispecific binding agents comprising a first binding site that specifically binds a therapeutic ocular target and a second binding site that specifically binds collagen II. |
| priorityDate |
2016-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |